Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study

被引:115
作者
Rukwied, R
Lischetzki, G
McGlone, F
Heyer, G
Schmelz, M
机构
[1] Univ Erlangen Nurnberg, Dept Physiol & Expt Pathophysiol, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Dept Dermatol, D-8520 Erlangen, Germany
[3] Unilever Res, Port Sunlight Lab, Wirral, Merseyside, England
关键词
atopic dermatitis; mast cell mediators; protein extravasation; pruritus;
D O I
10.1046/j.1365-2133.2000.03535.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
While histamine is the crucial mediator of pruritus in type 1 allergic reactions, its role in atopic dermatitis (AD) is unclear. In this study, the role of mast cell mediators in protein extravasation and pruritus was evaluated using intradermal microdialysis. The microdialysis capillaries were used to apply the mast cell degranulating substance compound 48/80 (C48/80; 0.05%) or histamine (0.01%) and also to deliver H1-blockers (cetirizine, 200 mu g mL(-1)) in nine AD patients and nine controls, Large pore size membranes (3000 kDa) enabled simultaneous analysis of protein extravasation. Itch sensation was measured psychophysically and weal and flare reaction were evaluated planimetrically. Protein extravasation induced by histamine and C48/80 was significantly reduced in AD patients. Blockade of H1-receptors by cetirizine significantly reduced C48/80-induced protein extravasation in AD patients and controls to an identical level. C48/80-induced pruritus was abolished by cetirizine in controls, whereas pruritus in AD patients was unchanged after H1 blockade. We conclude that mast cell mediators others than histamine are involved in C48/80-induced pruritus in AD patients. Whether the reduced capacity of AD patients to induce protein extravasation is of pathophysiological relevance for pruritus remains to be established.
引用
收藏
页码:1114 / 1120
页数:7
相关论文
共 58 条
[1]   ACTIVATION AND INHIBITION OF MEDIATOR RELEASE FROM SKIN MAST-CELLS - A REVIEW OF IN-VITRO EXPERIMENTS [J].
AMON, U ;
NITSCHKE, M ;
DIECKMANN, D ;
GIBBS, BF ;
WEHRHAHN, C ;
WOLFF, HH .
CLINICAL AND EXPERIMENTAL ALLERGY, 1994, 24 (12) :1098-1104
[2]  
Amon Ulrich, 1994, Journal of Dermatological Science, V7, P63, DOI 10.1016/0923-1811(94)90023-X
[3]  
ANDERSSON T, 1995, ACTA DERM-VENEREOL, V75, P343
[4]  
[Anonymous], ACTA DERM VENERE S92, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]
[5]   TOPICAL SODIUM CROMOGLYCATE IN THE MANAGEMENT OF ATOPIC ECZEMA - A CONTROLLED TRIAL [J].
ARIYANAYAGAM, M ;
BARLOW, TJG ;
GRAHAM, P ;
HALLSMITH, SP ;
HARRIS, JM .
BRITISH JOURNAL OF DERMATOLOGY, 1985, 112 (03) :343-348
[6]   IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects [J].
Barata, LT ;
Ying, S ;
Meng, Q ;
Barkans, J ;
Rajakulasingam, K ;
Durham, SR ;
Kay, AB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (02) :222-230
[7]   HISTAMINE, ANTIHISTAMINES AND ATOPIC ECZEMA [J].
BEHRENDT, H ;
RING, J .
CLINICAL AND EXPERIMENTAL ALLERGY, 1990, 20 :25-30
[8]   Human mast cell cytokines [J].
Bradding, P .
CLINICAL AND EXPERIMENTAL ALLERGY, 1996, 26 (01) :13-19
[9]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[10]  
BUSINCO L, 1986, ANN ALLERGY, V57, P433